Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979488248> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2979488248 endingPage "3942" @default.
- W2979488248 startingPage "3942" @default.
- W2979488248 abstract "Abstract Objective: The third-generation tyrosine kinase inhibitor (TKI) ponatinib can overcome many kinds of single mutations including T315I of Bcr-Abl1. Unfortunately, recent clinical studies have identified some new point mutations resistant to ponatinib and the other marketed TKIs. These mutations include compound mutations or T315M single mutation, which we called high level drug resistant mutations in this study. Therefore, it is an urgent task to find a potent small molecule inhibitors, which can overcome these high level drug resistant mutations. Methods: To screen for compounds that can overcome the high level drug resistant mutations of Bcr-Abl1, we firstly established genetic engineering cell models using the Ba/F3 cell line, including: (1) Ba/F3-Bcr-Abl1T315M; (2) Ba/F3-Bcr-Abl1T315I/E255V; (3) Ba/F3-Bcr-Abl1E255V/Y253H. The established cell lines were also carefully verified .Then we used these established cell models and others we have already obtained, including Ba/F3-Bcr-Abl1WT, Ba/F3-Bcr-Abl1T315I, and Ba/F3-Bcr- Abl1E255V, to screen an in-house chemical library. The most potent compound SKLB-518 was finally chosen to perform further studies both in vitro (cell and protein level) and in vivo (allograft subcutaneous cancer mice model). Results: In vitro assays, three marketed TKIs, namely imatinib, dasatinib, and ponatinib, were chosen as the references. The IC50 value of SKLB-518 to inhibit Ba/F3-Bcr-Abl1E255V/Y254H cells was 0.033 μM, which was more active by >100 times and 6.14 times than that of imatinib (IC50: >10 μM) and ponatinib (IC50:0.201μM), respectively, and comparable with dasatinib (IC50:0.028 μM). The IC50 of SKLB-518 to inhibit Ba/F3- Bcr-Abl1T315I/E255V cells was 0.094 μM, which was more potent by >100 times, 30~100 times, and 8.69 times than that of imatinib (IC50: >10 μM), dasatinib (IC50: 3~10 μM), and ponatinib (IC50: 0.817 μM), respectively. In vivo, thedata indicated that SKLB-518 could significantly inhibit tumor proliferation at the doses of 30 mg/kg/d and 45 mg/kg/d (%T/C was 62.1 and 72.5, respectively; both groups p<0.001), while ponatinib couldn't inhibit tumor growth at the 30 mg/kg/day dose (%T/C was 87.8, p=0.157). Immunohistochemical staining assays indicated that SKLB-518 at the doses of 45 mg/kg/d could potently inhibit Bcr-Abl1 downstream targets (Crkl and Stat5). Meanwhile, we didn't find severe toxicity of SKLB-518 in the effective doses both in cells and in mice. Conclusion:Independently developed small molecule SKLB- 518 might overcome the high level drug resistant mutations of Bcr-Abl1. Disclosures No relevant conflicts of interest to declare." @default.
- W2979488248 created "2019-10-18" @default.
- W2979488248 creator A5038846309 @default.
- W2979488248 creator A5077666079 @default.
- W2979488248 date "2016-12-02" @default.
- W2979488248 modified "2023-09-26" @default.
- W2979488248 title "A Potent Small Molecule Compound Might Overcome High Level Drug Resistant Mutations of Bcr-Abl1" @default.
- W2979488248 doi "https://doi.org/10.1182/blood.v128.22.3942.3942" @default.
- W2979488248 hasPublicationYear "2016" @default.
- W2979488248 type Work @default.
- W2979488248 sameAs 2979488248 @default.
- W2979488248 citedByCount "0" @default.
- W2979488248 crossrefType "journal-article" @default.
- W2979488248 hasAuthorship W2979488248A5038846309 @default.
- W2979488248 hasAuthorship W2979488248A5077666079 @default.
- W2979488248 hasConcept C104317684 @default.
- W2979488248 hasConcept C170493617 @default.
- W2979488248 hasConcept C185592680 @default.
- W2979488248 hasConcept C207001950 @default.
- W2979488248 hasConcept C2777583451 @default.
- W2979488248 hasConcept C2777752497 @default.
- W2979488248 hasConcept C2778729363 @default.
- W2979488248 hasConcept C2779536868 @default.
- W2979488248 hasConcept C2780381907 @default.
- W2979488248 hasConcept C3019892230 @default.
- W2979488248 hasConcept C42362537 @default.
- W2979488248 hasConcept C43907098 @default.
- W2979488248 hasConcept C501734568 @default.
- W2979488248 hasConcept C502942594 @default.
- W2979488248 hasConcept C54355233 @default.
- W2979488248 hasConcept C62478195 @default.
- W2979488248 hasConcept C81885089 @default.
- W2979488248 hasConcept C86803240 @default.
- W2979488248 hasConcept C98274493 @default.
- W2979488248 hasConceptScore W2979488248C104317684 @default.
- W2979488248 hasConceptScore W2979488248C170493617 @default.
- W2979488248 hasConceptScore W2979488248C185592680 @default.
- W2979488248 hasConceptScore W2979488248C207001950 @default.
- W2979488248 hasConceptScore W2979488248C2777583451 @default.
- W2979488248 hasConceptScore W2979488248C2777752497 @default.
- W2979488248 hasConceptScore W2979488248C2778729363 @default.
- W2979488248 hasConceptScore W2979488248C2779536868 @default.
- W2979488248 hasConceptScore W2979488248C2780381907 @default.
- W2979488248 hasConceptScore W2979488248C3019892230 @default.
- W2979488248 hasConceptScore W2979488248C42362537 @default.
- W2979488248 hasConceptScore W2979488248C43907098 @default.
- W2979488248 hasConceptScore W2979488248C501734568 @default.
- W2979488248 hasConceptScore W2979488248C502942594 @default.
- W2979488248 hasConceptScore W2979488248C54355233 @default.
- W2979488248 hasConceptScore W2979488248C62478195 @default.
- W2979488248 hasConceptScore W2979488248C81885089 @default.
- W2979488248 hasConceptScore W2979488248C86803240 @default.
- W2979488248 hasConceptScore W2979488248C98274493 @default.
- W2979488248 hasIssue "22" @default.
- W2979488248 hasLocation W29794882481 @default.
- W2979488248 hasOpenAccess W2979488248 @default.
- W2979488248 hasPrimaryLocation W29794882481 @default.
- W2979488248 hasRelatedWork W1519449155 @default.
- W2979488248 hasRelatedWork W1975751393 @default.
- W2979488248 hasRelatedWork W2013963600 @default.
- W2979488248 hasRelatedWork W2100041900 @default.
- W2979488248 hasRelatedWork W2155107050 @default.
- W2979488248 hasRelatedWork W2323167910 @default.
- W2979488248 hasRelatedWork W2552820660 @default.
- W2979488248 hasRelatedWork W2572120445 @default.
- W2979488248 hasRelatedWork W2620094379 @default.
- W2979488248 hasRelatedWork W2808764596 @default.
- W2979488248 hasVolume "128" @default.
- W2979488248 isParatext "false" @default.
- W2979488248 isRetracted "false" @default.
- W2979488248 magId "2979488248" @default.
- W2979488248 workType "article" @default.